

Stemline Therapeutics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 19-Jun-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 10

[Return to Table of Contents](#)

Stemline Therapeutics Inc

COMPANY OVERVIEW

Company Name	Stemline Therapeutics Inc
Parent Company Name	Stemline Therapeutics Inc
Website	http://www.stemline.com/
Country	US
Number of Drugs in Active Development	13
Number of Inactive Drugs	2
Number of Patents as Owner	5
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Cancer, Acute myelogenous leukemia, Bladder tumor, Chronic myelocytic leukemia, Glioma, Hematological neoplasm, Myelodysplastic syndrome, Neoplasm, Solid tumor, Myeloid leukemia
Key Target-based Actions	IL-3 receptor modulator, CDw123 modulator, Frizzled receptor modulator, Glypican-3 modulator, Notch receptor modulator, Prominin 1 modulator, Smoothed receptor modulator, Tie 1 tyrosine kinase receptor modulator, CDw123 antagonist
Key Technologies	Biological therapeutic, Parenteral formulation unspecified, Monoclonal antibody, Small molecule therapeutic, Monoclonal antibody conjugated, Antibody conjugated, Imaging

COMPANY PROFILE

SUMMARY

Stemline Therapeutics Inc is a clinical stage biopharmaceutical company that develops oncology compounds directed at cancer stem cell targets and tumor bulks.

FINANCIAL

In May 2013, the company planned to raise \$60 million gross proceeds from an underwritten public offering of 4,137,931 shares of its common stock at \$14.50 per share. The underwriters were granted a 30-day option to buy up to 620,689 additional shares of common stock. Later that month, the offering was closed. Later that month, the underwriters exercised in full their option to purchase an additional 620,689 shares of common stock. At that time, the total gross proceeds were expected to be approximately \$69,000,000 and the closing of the option to purchase additional shares was expected to occur on or about May 28, 2013.

In January 2013, the company was to raise gross proceeds of \$33,176,440, through an IPO of 3,317,644 shares of common stock priced at \$10 each. Underwriters were granted a 45-day option to purchase additional shares up to 497,647 shares of common stock to cover over-allotments. The offering was expected to close on January 31, 2013. At that time, shares were expected to be traded on the NASDAQ market on January 29, 2013. In January 2013, underwriters exercised in full their over-allotment option increasing gross proceeds from the offering to \$38,152,910; later that month, the offering was closed. Later in January 2013, the company began trading on the NASDAQ stock market.

In April 2012, the company had filed a registration statement with the SEC for a proposed IPO of its common stock.

In April 2008, Stemline raised \$12.5 million from a financing round.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	13	2	15
Hematological disease	2	2	4
Genitourinary disease	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	11
No Development Reported	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	0	0	1	0	1
Drug - Development Services	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
-------------------	---------	-----

[Return to Table of Contents](#)



Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	0	3
Hematological disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 1	0	2
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Hematological disease	1	0	1
Neoplasm	5	0	5

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

SL-401

Drug Name	SL-401
Key Synonyms	
Originator Company	Duke University
Active Companies	Stemline Therapeutics Inc
Inactive Companies	Duke University
Highest Status	Phase 2 Clinical
Active Indications	Chronic myelocytic leukemia, Acute myelogenous leukemia, Myelodysplastic syndrome, Neoplasm, Cancer
Target-based Actions	IL-3 receptor modulator, CDw123 modulator
Other Actions	Anticancer, Immunotoxin
Technologies	Protein conjugated, Intravenous formulation, Infusion, Biological therapeutic, Protein recombinant
Last Change Date	12-Jun-2013

SL-701

Drug Name	SL-701
Key Synonyms	
Originator Company	University of Pittsburgh
Active Companies	Stemline Therapeutics Inc
Inactive Companies	University of Pittsburgh
Highest Status	Phase 2 Clinical
Active Indications	Glioma
Target-based Actions	
Other Actions	Therapeutic vaccine, Anticancer
Technologies	Systemic formulation unspecified, Biological therapeutic, Peptide, Adult stem cell therapy
Last Change Date	08-Jan-2013

[Return to Table of Contents](#)



SL-101

Drug Name	SL-101
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hematological neoplasm
Target-based Actions	IL-3 receptor modulator, CDw123 modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody conjugated, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	10-Dec-2012

SL-301

Drug Name	SL-301
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Solid tumor
Target-based Actions	Notch receptor modulator
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	10-Mar-2011

[Return to Table of Contents](#)



SL-201

Drug Name	SL-201
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Unspecified drug target, Anticancer
Technologies	Small molecule therapeutic
Last Change Date	10-Mar-2011

SL-601

Drug Name	SL-601
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bladder tumor
Target-based Actions	
Other Actions	Anticancer antibody, Unspecified drug target
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	10-Mar-2011

[Return to Table of Contents](#)

mAb based glypican-3 modulators (cancer), Stemline Therapeutics

Drug Name	mAb based glypican-3 modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Glypican-3 modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	18-Sep-2012

mAb based Tie-1 modulators (cancer), Stemline Therapeutics

Drug Name	mAb based Tie-1 modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Tie 1 tyrosine kinase receptor modulator
Other Actions	Anticancer protein kinase inhibitor, Anticancer monoclonal antibody
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	16-Mar-2011

[Return to Table of Contents](#)

mAb based CD-133 modulators (cancer), Stemline Therapeutics

Drug Name	mAb based CD-133 modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Prominin 1 modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	15-Mar-2011

small molecule therapeutics (cancer), Stemline Therapeutics

Drug Name	small molecule therapeutics (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Stem cell inhibitor, Anticancer
Technologies	Small molecule therapeutic
Last Change Date	18-Sep-2012

[Return to Table of Contents](#)



mAb based frz receptor modulators (cancer), Stemline Therapeutics

Drug Name	mAb based frz receptor modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Frizzled receptor modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	18-Sep-2012

mAb based Smo modulators (cancer), Stemline Therapeutics

Drug Name	mAb based Smo modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Smoothened receptor modulator
Other Actions	Anticancer monoclonal antibody
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	16-Mar-2011

[Return to Table of Contents](#)

mAb based Ptc modulators (cancer), Stemline Therapeutics

Drug Name	mAb based Ptc modulators (cancer), Stemline Therapeutics
Key Synonyms	
Originator Company	Stemline Therapeutics Inc
Active Companies	Stemline Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Anticancer monoclonal antibody, Unspecified drug target
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	16-Mar-2011

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)